Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: belapectin, olitigaltin, davanat | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 706 | 0.67 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2461
Sealed predictions
- LGALS3 in dopamine neurons, braak-0.28 (p 0.473) → +0.00 (p 1.000)receipt 2469
In the sealed studies
- An antigen-presenting microglial response: did not hold
Swarm cases
receipt 2469: LGALS3 in dopamine neurons, braak
- power
- full sample -0.17 (p 0.493, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.18 (p 0.465, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.515, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.08, sign flips 0; without severely affected donors -0.17 (p 0.493, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LGALS3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts